Altered arachidonic acid-mediated responses in the perfused kidney of the streptozotocin-induced diabetic rat

Journal of Smooth Muscle Research

Volumn 42, Issue 5, 2006, Pages 171-187

  Kamata, Katsuo ^a   Hosokawa, Masao ^a   Matsumoto, Takayuki ^a   Kobayashi, Tsuneo ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Arachidonic acid; Kidney; Perfusion pressure; Rat; Streptozotocin

Indexed keywords

7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ARACHIDONIC ACID; BAICALEIN; CLOTRIMAZOLE; CYTOCHROME P450 INHIBITOR; FUREGRELATE; INDOMETACIN; LIPOXYGENASE INHIBITOR; METHOXAMINE; PROADIFEN; PROSTAGLANDIN SYNTHASE INHIBITOR; STREPTOZOCIN; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; KIDNEY PERFUSION; MALE; NONHUMAN; RAT; STREPTOZOCIN DIABETES; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ARACHIDONIC ACID; CYCLOOXYGENASE INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; INDOMETHACIN; KIDNEY; MALE; MUSCLE CONTRACTION; MUSCLE RELAXATION; MUSCLE TONUS; MUSCLE, SMOOTH, VASCULAR; PERFUSION; PROADIFEN; RATS; RATS, WISTAR; REGIONAL BLOOD FLOW; STREPTOZOCIN;

EID: 33845478596     PISSN: 09168737     EISSN: None     Source Type: Journal    
DOI: 10.1540/jsmr.42.171     Document Type: Article

References (53)

1. 2+ sensitization of smooth muscle contraction through activation of Rho-kinase. Pflugers Arch. 441: 596-603.
2. Bruce, J.I. and Elliott, A.C. (2000). Pharmacological evaluation of the role of cytochrome P450 in intracellular calcium signaling in rat pancreatic acinar cells. Br. J. Pharmacol. 131: 761-771.
3. Carroll, M.A., Balazy, M., Margiotta, P., Falck, J.R. and McGiff, J.C. (1993). Renal vasodilator activity of 5,6-epoxyeicosatrienoic acid depends upon conversion by cyclooxygenase and release of prostaglandins. J. Biol. Chem. 268: 12260-12266.
4. Cheng, H.F., Wang, C.J., Moeckel, G.W., Zhang, M.Z., McKanna, J.A. and Harris, R.C. (2002). Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int. 62: 929-939.
5. Cheng, H.F. and Harris, R.C. (2004). Cyclooxygenases, the kidney, and hypertension. Hypertension 43: 525-530.
6. De Vriese, A.S., Verbeuren, T.J., Van de Voorde, J., Lameire, N.H. and Vanhoutte, P.M. (2000). Endothelial dysfunction in diabetes. Br. J. Pharmacol. 130: 963-974.
7. Fitzgerald, S.M., Kemp-Harper, B.K., Tare, M. and Parkington, H.C. (2005). Role of endothelium-derived hyperpolarizing factor in endothelial dysfunction during diabetes. Clin. Exp. Pharmacol. Physiol. 32: 482-487.
8. Fleming, I. (2001). Cytochrome p450 and vascular homeostasis. Circ. Res. 89: 753-762.
9. Fukao, M., Hattori, Y., Kanno, M., Sakuma, I. and Kitabatake, A. (1997). Alteration in endothelium-dependent hyperpolarization and relaxation in mesenteric arteries from streptozotocin-induced diabetic rats. Br. J. Pharmacol. 121: 1383-1391.
10. Gong, M.C., Fuglsang, A., Alessi, D., Kobayashi, S., Cohen, P., Somlyo, A.V. and Somlyo, A.P. (1992). Arachidonic acid inhibits myosin light chain phosphatase and sensitizes smooth muscle to calcium. J. Biol. Chem. 267: 21492-21498.
11. Hirano, K., Hirano, M. and Kanaide, H. (2004). Regulation of myosin phosphorylation and myofilament Ca2+ sensitivity in vascular smooth muscle. J. Smooth Muscle Res. 40: 219-236.
12. Imig, J.D. (2000). Eicosanoid regulation of the renal vasculature. Am. J. Physiol. 279: F965-F981.
13. Imig, J.D. (2006). Eicosanoids and renal vascular function in diabetes. Clin. Sci. 111: 21-34.
14. Kamata, K. and Hayashi, T. (1999). Effects of chronic treatment with the spontaneous nitric oxide releaser FK409 on vascular responses in established streptozotocin-induced diabetic rat. Res. Commun. Mol. Pathol. Pharmacol. 103: 275-294.
15. Kamata, K. and Hosokawa, M. (1997a). Characteristics of vasodilatation induced by cyclopiazonic acid in the rat perfused kidney. Res. Commun. Mol. Pathol. Pharmacol. 96: 147-156.
16. Kamata, K. and Hosokawa, M. (1997b). Endothelial dysfunction in the perfused kidney from the streptozotocin-induced diabetic rat. Res. Commun. Mol. Pathol. Pharmacol. 96: 57-70.
17. Kamata, K. and Kobayashi, T. (1996). Changes in superoxide dismutase mRNA expression by streptozotocin-induced diabetes. Br. J. Pharmacol. 119: 583-589.
18. Kamata, K., Kobayashi, T., Matsumoto, T., Kanie, N., Oda, S., Kaneda, A. and Sugiura, M. (2005). Effects of chronic administration of fruit extract (Citrus unshiu Marc) on endothelial dysfunction in streptozotocin-induced diabetic rats. Biol. Pharm. Bull. 28: 267-270.
19. Kamata, K., Miyata, N. and Kasuya, Y. (1989). Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats. Br. J. Pharmacol. 97: 614-618.
20. Kamata, K. and Mizutani, K. (1999). Changes in angiotensin converting enzyme activity in the renal vascular bed of streptozotocin-induced diabetic rat. Res. Commun. Mol. Pathol. Pharmacol. 104: 181-192.
21. Kamata, K., Nakajima, M. and Sugiura, M. (1999). Effects of superoxide dismutase on the acetylcholine-induced relaxation response in cholesterol-fed and streptozotocin-induced diabetic mice. J. Smooth Muscle Res. 35: 33-46.
22. Kamata, K. and Yamashita, K. (1999). Insulin resistance and impaired endothelium-dependent renal vasodilatation in fructose-fed hypertensive rats. Res. Commun. Mol. Pathol. Pharmacol. 103: 195-210.
23. Kambham, N., Markowitz, G.S., Valeri, A.M., Lin, J. and D'Agati, V.D. (2001). Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 59: 1498-1509.
24. Kobayashi, T., Matsumoto, T. and Kamata, K. (2000). Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocin-induced diabetic rats. Br. J. Pharmacol. 131: 231-238.
25. Kobayashi, T., Matsumoto, T. and Kamata, K. (2005). The PI3-K/Akt pathway: roles related to alterations in vasomotor responses in diabetic models. J. Smooth Muscle Res. 41: 283-302.
26. Kobayashi, T., Oishi, K., Hayashi, Y., Matsumoto, T. and Kamata, K. (2006). Changes in aortic endothelial gene expressions and relaxation responses following chronic short-term insulin treatment in diabetic rats. Atherosclerosis 185: 47-57.
27. Kobayashi, T., Taguchi, K., Yasuhiro, T., Matsumoto, T. and Kamata, K. (2004). Impairment of PI3-K/Akt pathway underlies attenuated endothelial function in aorta of type 2 diabetic mouse model. Hypertension 44: 956-962.
28. Komers, R., Lindsley, J.N., Oyama, T.T., Schutzer, W.E., Reed, J.F., Mader, S.L. and Anderson, S. (2001). Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J. Clin. Invest. 107: 889-898.
29. Kwan, C.Y. (1999). Membrane abnormalities of vascular smooth muscle of mesenteric arteries of spontaneous diabetic BB rats. J. Smooth Muscle Res. 35: 77-86.
30. Makino, A. and Kamata, K. (2002). Effects of chronic administration of L-arginine on vasoactive responses induced by endothelin-1 and its plasma level in streptozotocin-induced diabetic rats. J. Smooth Muscle Res. 38: 101-115.
31. Makino, A., Ohuchi, K. and Kamata, K. (2000). Mechanisms underlying the attenuation of endothelium-dependent vasodilatation in the mesenteric arterial bed of the streptozotocin-induced diabetic rat. Br. J. Pharmacol. 130: 549-556.
32. Matsumoto, T., Kobayashi, T. and Kamata, K. (2003a). Alterations in EDHF-type relaxation and phosphodiesterase activity in mesenteric arteries from diabetic rats. Am. J. Physiol. 285: H283-H291.
33. Matsumoto, T., Kobayashi, T. and Kamata, K. (2003b). Phosphodiesterases in the vascular system. J. Smooth Muscle Res. 39: 67-86.
34. Matsumoto, T., Kobayashi, T. and Kamata, K. (2006a). A therapeutic target for microvascular complications in diabetes: endothelium-derived hyperpolarizing factor. Curr. Cardiol. Rev. 2: 185-191.
35. Matsumoto, T., Miyamori, K., Kobayashi, T. and Kamata, K. (2006b). Apocynin normalizes hyperreactivity to phenylephrine in mesenteric arteries from cholesterol-fed mice by improving endothelium-derived hyperpolarizing factor response. Free Radic. Biol. Med. 41: 1289-1303.
36. Matsumoto, T., Miyamori, K., Kobayashi, T. and Kamata, K. (2006c). Specific impairment of endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from streptozotocin-induced diabetic mice. Vascul. Pharmacol. 44: 450-460.
37. Matsumoto, T., Kobayashi, T., Wakabayashi, K. and Kamata, K. (2005). Cilostazol improves endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from diabetic rats. Am. J. Physiol. 289: H1933-H1940.
38. Matsumoto, T., Wakabayashi, K., Kobayashi, T. and Kamata, K. (2004). Diabetes-related changes in cAMP-dependent protein kinase activity and decrease in relaxation response in rat mesenteric artery. Am. J. Physiol. 287: H1064-H1071.
39. McGiff, J.C. and Quilley, J. (1999). 20-HETE and the kidney: resolution of old problems and new beginnings. Am. J. Physiol. 277: R607-R623.
40. Miyata, N. and Roman, R.J. (2005). Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J. Smooth Muscle Res. 41: 175-193.
41. Natarajan, R. and Nadler, J.L. (2004). Lipid inflammatory mediators in diabetic vascular disease. Arterioscler. Thromb. Vasc. Biol. 24: 1542-1548.
42. Pfister, S.L., Spitzbarth, N., Edgemond, W. and Campbell, W.B. (1996). Vasorelaxation by an endothelium-derived metabolite of arachidonic acid. Am. J. Physiol. 270: H1021-H1030.
43. Pinto, A., Abraham, N.G. and Mullane, K.M. (1987). Arachidonic acid-induced endothelial-dependent relaxations of canine coronary arteries: contribution of a cytochrome P-450-dependent pathway. J. Pharmacol. Exp. Ther. 240: 856-863.
44. Poston, L. and Taylor, P.D. (1995). Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. Clin Sci. 88: 251-252.
45. Roman, R.J. (2002). P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82: 131-185.
46. Roman, R.J., Maier, K.G., Sun, C.W., Harder, D.R. and Alonso-Galicia, M. (2000). Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids. Clin. Exp. Pharmacol. Physiol. 27: 855-865.
47. Sekiguchi, F., Matsuda, K., Shimamura, K., Takeuchi, K. and Sunano, S. (1998). Involvement of endothelium-derived factors in controlling the active tone of smooth muscle in aorta from hypertensive rats. J. Smooth Muscle Res. 34: 221-232.
48. Shimamura, K., Kimura, S., Zhou, M., Wang, Y., Toba, M., Ohashi, A., Higuchi, T., Kawaguchi, H. and Kitamura, K. (2005). Evidence for the involvement of the cyclooxygenase-metabolic pathway in dicrofenac-induced inhibition of spontaneous contraction of rat portal vein smooth muscle cells. J. Smooth Muscle Res. 41: 195-206.
49. Somlyo, A.P. and Somlyo, A.V. (1994). Signal transduction and regulation in smooth muscle. Nature 372: 231-236.
50. Sowers, J.R. and Epstein, M. (1995). Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension 26: 869-879.
51. Triggle, C.R., Hollenberg, M., Anderson, T.J., Ding, H., Jiang, Y., Ceroni, L., Wiehler, W.B., Ng, E.S., Ellis, A., Andrews, K., McGuire, J.J. and Pannirselvam, M. (2003). The endothelium in health and disease - a target for therapeutic intervention. J. Smooth Muscle Res. 39: 249-267.
52. Vivian, E.M. and Rubinstein, G.B. (2002). Pharmacologic management of diabetic nephropathy. Clin. Ther. 24: 1741-1756.
53. Vizioli, E.O., Spadin, M.D., Correa, F.M., Viaro, F., Evora, P.R. and Chies, A.B. (2005). Acetylcholine-induced aortic relaxation studied in sulbutamol treated rats. J. Smooth Muscle Res. 41: 271-281.